Viz.ai Collaborates with Microsoft Read the Announcement

Contact Us
Providers
Viz.ai One

Viz Neuro Suite
Large Vessel Occlusion (LVO)
CT Perfusion (CTP)
Hemorrhage
Cerebral Aneurysm
Subdural Hemorrhage
Post Acute Stroke

Viz Vascular Suite
Pulmonary Embolism
Aortic Disease

Viz Cardio Suite
Hypertrophic Cardiomyopathy
Post Acute Stroke

Viz Radiology Suite

Viz Trauma Suite
Life Sciences

Life Sciences

Discover how we work with life sciences partners to drive patient care innovation.

Go to Life Sciences
Customers

Support

Help Center

Customer Resources

User Guides (EU only)

Viz Academy
Clinical Research

Publications

HCM Education Series
Resources

Webinars

Events

Press & News

White papers

Blog

Trust Center
About Us

Our Story

Leadership

Careers
Contact Us
Home /

Defying the silent storm:

Defying the silent storm:

How AI can help with the detection and accelerated treatment of atherosclerotic disease

AI can detect high-risk atherosclerotic cardiovascular disease (ASCVD) patients and streamline their journey to treatment

Nearly 1 in 10 Americans suffer from ASCVD today.1 It is estimated that more than 50% of these patients are not on lipid-lowering therapy.2 Moreover, studies suggest that over 65% of patients who are on lipid-lowering treatment do not achieve a guideline-recommended cholesterol level.3 This high-risk group of patients are at a higher risk of a subsequent cardiovascular episode.

PCSK9 inhibitors offer an efficacious therapeutic solution for high risk patients — approximately 75% of the post-heart attack and post-stroke cohort, today only a quarter of ASCVD patients are getting their cholesterol levels checked post-ASCVD episode, and many of these patients are missing these guideline-supported therapies.4

1 Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;Mar 17
2 Alexa C. Klimchak, Miraj Y. Patel, Şerban R. Iorga, Natasha Kulkarni, Nathan D. Wong,
Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States, American Journal of Preventive Cardiology, Volume 1, 2020
3 ACC TRANSFORM LDL-C Risk initiative
4 Sara N Levintow, Stephanie R Reading, Sina Noshad, Sophie E Mayer, Catherine Wiener, Bassim Eledath, Jason Exter & M Alan Brookhart (2022) Lipid Testing Trends Before and After Hospitalization for Myocardial Infarction Among Adults in the United States, 2008–2019, Clinical Epidemiology, 14:, 737-748.

An AI-powered Solution

Viz.ai is a comprehensive solution that not only detects high-risk ASCVD patients but also prevents patient fall-out. Through our seamless EHR integrations, Viz.ai empowers healthcare professionals and care teams to take immediate action at the point of care, facilitating prompt diagnosis and directing patients to optimal therapy. This represents the essence of AI-powered care coordination, which in turn leads to transformative improvements in patient outcomes. Accelerating time to therapy for high-risk ASCVD patients — we’re partnering with biopharma and medtech companies to enhance the patient journey to treatment.

Viz Connect

Viz Connect offers provider workflows, directing cryptogenic stroke patients from neurology to cardiology. Many cryptogenic strokes have a cardiac origin therefore efficient care coordination is a critical process in the patient journey. Viz Connect customers report a 2 - 3x uplift in referrals to cardiology, ensuring patients receive appropriate follow-up diagnostic tests.

Latest news and insights